Applications of SGLT2 inhibitors beyond glycaemic control

Nature Reviews Nephrology, Published online: 26 April 2024; doi:10.1038/s41581-024-00836-yHere, the authors discuss the beneficial effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors for a range of clinical outcomes beyond glucose lowering, including kidney and cardiovascular protection. They also discuss the need for implementation and adherence initiatives to help translate the benefits of these agents into real-world clinical outcomes.

Source: Nature Reviews Nephrology - April 26, 2024 Category: Urology & Nephrology Authors: Daniel V. O ’Hara Carolyn S. P. Lam John J. V. McMurray Tae Won Yi Samantha Hocking Jessica Dawson Smriti Raichand Andrzej S. Januszewski Meg J. Jardine Source Type: research